Trial Profile
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs SB 728 T (Primary) ; Cyclophosphamide
- Indications HIV infections
- Focus Adverse reactions
- Sponsors Sangamo Therapeutics
- 01 Jul 2019 Status changed from active, no longer recruiting to completed.
- 06 Jan 2017 According to a Sangamo Therapeutics media release, this trial was originally conducted by Sangamo BioSciences but later on this company's name changed to Sangamo Therapeutics.
- 06 Jan 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Jun 2018.